Loading…
Loading…
SLDX does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SLDX and 80,000+ other tickers.
See exactly how SLDX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SLDX and 80,000+ other tickers.
Stella Diagnostics Inc. is a molecular diagnostics firm primarily focused on advancing patient care strategies for individuals afflicted with severe esophageal disorders. The company's specialized clinical tests furnish physicians with crucial information regarding the molecular makeup of a patient's tissue, enabling them to ascertain if the disease is static, deteriorating, or undergoing malignant transformation. Additionally, Stella Diagnostics is engaged in the development of innovative diagnostic tools intended to provide healthcare professionals with enhanced molecular insights compared…
STLA101 panel of 8 proprietary biomarkers can differentiate between the stages of esophageal cancer invasion and has previously demonstrated predictive power of detecting hallmarks of carcinogenesis in precancerous esophageal tissue STLA101 panel of 8 proprietary biomarkers can differentiate between the stages of esophageal cancer invasion and has previously demonstrated predictive power of detecting hallmarks of carcinogenesis in precancerous esophageal tissue
DENVER, March 02, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancerous esophageal diseases, today announced its abstract, “Multi-Institutional Study Assessing STLA101 Assay Performance for the Detection of Cancerous Progression in Barrett's Esophagus”, has been selected for the Next Big Thing session at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2022 Annual Meeting. The congress will be held March 16-19, 2022, at the Colorado Convention Center in Denver.